Am­gen, Sanofi back a round for re­al-world ev­i­dence plat­form tech; Dai­ichi Sanky­o's pex­i­dar­tinib se­cures speedy FDA re­view

→ Ae­tion has gar­nered $27 mil­lion from a new ven­ture round that in­cludes some of the biggest names in health­care. The com­pa­ny plans to use the cash to build up its plat­form of re­al-world ev­i­dence da­ta, a bur­geon­ing field where pa­tient out­comes can in­form drug mak­ers and mar­keters what works, when. The round was backed by Am­gen Ven­tures, Sanofi, UCB, McKesson Ven­tures, Hori­zon Health Ser­vices and oth­ers.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER